MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy-Werbin, Max, del Rey-Vergara, Raúl, Galindo-Campos, Miguel Alejandro, Moliner, Laura, Arriola, Edurne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827355/
https://www.ncbi.nlm.nih.gov/pubmed/31547040
http://dx.doi.org/10.3390/cancers11101404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827355/
https://www.ncbi.nlm.nih.gov/pubmed/31547040
http://dx.doi.org/10.3390/cancers11101404

Ejemplares similares